Article Text

Download PDFPDF

Intravascular radiotherapy: restenosis and more?
  1. Department of Cardiology, Clinic for Internal Medicine II
  2. University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna Austria
  3. email: pwexberg{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

At the end of the 1970s balloon angioplasty emerged as a new hope in the treatment of coronary atherosclerosis.1 A decade later, the implantation of endovascular stents2 did not only reduce the number of acute complications of percutaneous coronary interventions, but also the incidence of restenosis.3 Now, as we begin the new millennium, intravascular radiotherapy promises to lower the restenosis rate further and has been shown to be especially effective in treatment of in-stent restenosis.4

Restenosis develops as a response to injury, mediated by a complex interaction of an inflammatory process, thrombus formation, proliferation and migration of smooth muscle cells (SMCs), expression of growth factors, matrix synthesis, and finally vascular remodelling.5 The antiproliferative effects of ionising radiation, which are widely used in treating various benign and malignant proliferative diseases, are based on the interaction of primary (β radiation) or secondary (γ radiation) electrons with biochemical bonds in cellular DNA,6 and on subsequent changes in gene expression that finally lead to a reduction of cell growth. In cell culture and various animal models numerous radioactive devices (wires, seeds, stents, liquid filled balloons) have been proven to reduce SMC proliferation successfully.7 In some studies even a decreased degree of constrictive remodelling was noted, which was attributed to a reduction of the adventitial reaction to balloon injury (myofibroblast proliferation).8 Most of the previously conducted clinical trials on vascular brachytherapy successfully lowered restenosis rates with both β and γ radiation4 ,9; however, aneurysm development after high dose irradiation,10 and the “candy wrapper” stenosis observed after implantation of radioactive stents, remain important limitations that deserve careful examination in both experimental and clinical studies.

Restenosis is clinically rather benign and mostly presents as stable angina, whereas the final, often fatal event in atherosclerosis is plaque rupture in haemodynamically non-significant lesions.11 The unstable plaque consists of SMCs, macrophages, and foam cells (“lipid core”), typically calcified and necrotic features, and a thin fibrous cap which is prone to fissuring. Macrophages play a major role in unstable angina by various means. They synthesise matrix degrading metalloproteinases12 which destabilise the fibrous cap and thus facilitate plaque rupture induced by shear stress. Macrophages also release proinflammatory cytokines, which in part stimulate SMC proliferation, and tissue factor11, the initiating protein in the extrinsic coagulation cascade. At plaque rupture, the exposure of circulating blood to thrombogenic proteins in the subendothelium rapidly induces thrombosis. The site of plaque rupture, most frequently the plaque shoulder, shows evidence of an ongoing inflammatory process, marked by T lymphocytes, macrophages, and focally raised temperature.13 ,14 The clinical impact of inflammation in the outcome of acute coronary syndromes was recently elucidated by reports on the predicting value of C reactive protein in patients with unstable angina and acute myocardial infarction.15

We hypothesise that local irradiation may be used to calm the inflammatory process in the unstable atherosclerotic plaque. Although dose finding, risk stratification, and assessment of the underlying biological mechanisms are still subject to intense investigations, radiotherapy for treatment of inflammation has been integrated into clinical routine for decades.16 Being an empirically based form of antiphlogistic therapy, it is used in a variety of benign diseases, such as hydradenitis, parotitis, panaritium, epicondylitis, or heterotopic ossification after orthopaedic surgery.16-18 Recently it has been shown that radiotherapy modulates the nitric oxide pathway in stimulated macrophages,19 which may in part explain the mitigated inflammatory reaction after irradiation of diseases involving macrophages, such as heterotopic ossification.20 Regarding vascular brachytherapy, Rubin and colleagues21 observed a pronounced reduction of invading monocytes and adventitial macrophages after irradiation of balloon injured rat carotids, corresponding to decreased neointima formation. This report emphasises the anti-inflammatory potential of vascular brachytherapy, although the mechanisms of macrophage reduction are not yet clear. In unstable plaques, reduction of macrophages might firstly result in a lower amount of metalloproteinases. Cessation of their matrix degrading activity will in consequence lessen the degree of the fibrous cap's destabilisation. Secondly, the emerging decrease in tissue factor synthesis will additionally moderate thrombogenicity after eventual plaque fissuring, and thirdly, the persisting macrophages will be impaired in certain pathways of inflammatory reactions, leading to a general mitigation of the inflammatory process in the arterial wall. Taken together, macrophage reduction may suppress the occurrence of plaque rupture and thrombosis, which mainly determine the patient's risk for development of acute coronary syndromes.

Thorough testing in experimental settings will be necessary to clarify the feasibility of using vascular brachytherapy in acute coronary interventions, and to determine the possible negative sequelae of macrophage reduction (for example, promoted formation of the thrombogenic lipid core by apoptotic macrophages,22upregulated expression of matrix degrading and/or thrombogenic factors by apoptotic cells, and induction of inflammatory processes in non-atherosclerotic vessel segments23). Although there has been no evidence of an increased apoptosis rate after experimental vascular brachytherapy so far,24 these considerations have to be taken into account regarding differences between stable and unstable, or primary and restenotic, lesions.

If irradiation modulates inflammatory processes in the unstable plaque, it could lead to a significant decrease in major adverse cardiac events. This may open a new indication for intravascular brachytherapy as a novel local anti-inflammatory treatment for unstable angina.